External Natural History Controlled, Open-Label Intervention Study to Assess the Efficacy and Safety of Long-Term Treatment With Raxone® in Leber's Hereditary Optic Neuropathy (LHON)

Trial Profile

External Natural History Controlled, Open-Label Intervention Study to Assess the Efficacy and Safety of Long-Term Treatment With Raxone® in Leber's Hereditary Optic Neuropathy (LHON)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Idebenone (Primary)
  • Indications Leber's hereditary optic atrophy
  • Focus Therapeutic Use
  • Acronyms LEROS
  • Sponsors Santhera Pharmaceuticals
  • Most Recent Events

    • 23 Aug 2016 Status changed from not yet recruiting to recruiting.
    • 29 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top